We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+30.18%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$937M
AUM Growth
+$390M
Cap. Flow
+$279M
Cap. Flow %
29.82%
Top 10 Hldgs %
69.5%
Holding
35
New
9
Increased
14
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$42.5M
2
WVE icon
Wave Life Sciences
WVE
+$33.6M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$28M
4
DBVT
DBV Technologies
DBVT
+$24.1M
5
PTCT icon
PTC Therapeutics
PTCT
+$21.5M

Top Sells

Rank Stock Value
1
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$10.3M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$7.01M
3
ARDM
Aradigm Corp Common Stock
ARDM
+$6.7M
4
RGLS
Regulus Therapeutics
RGLS
+$558K

Sector Composition

Rank Sector Weight
1 Healthcare 94.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$111M 11.87%
900,000
+75,000
+9% +$8.91M
ONC
2
BeOne Medicines Ltd
ONC
$32.8B
$106M 11.3%
630,000
+30,000
+5% +$4.06M
PTCT icon
3
PTC Therapeutics
PTCT
$5.64B
$70.2M 7.49%
2,600,000
+850,000
+49% +$21.5M
ESPR
4
DELISTED
Esperion Therapeutics
ESPR
$65.1M 6.95%
900,000
+100,000
+13% +$7.34M
ODT
5
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$59.9M 6.39%
2,826,938
+100,000
+4% +$2.36M
MGNX icon
6
MacroGenics
MGNX
$235M
$55.4M 5.91%
2,200,000
– –
WVE icon
7
Wave Life Sciences
WVE
$1.09B
$54.1M 5.77%
1,350,000
+800,000
+145% +$33.6M
LOXO
8
DELISTED
Loxo Oncology, Inc
LOXO
$46.1M 4.93%
+400,000
New +$42.5M
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$42.1M 4.5%
1,372,510
– –
MDCO
10
DELISTED
Medicines Co
MDCO
$41.2M 4.39%
1,250,000
+500,000
+67% +$15.6M
RCKT icon
11
Rocket Pharmaceuticals
RCKT
$340M
$36.9M 3.93%
1,966,051
+1,716,051
+686% +$28M
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
$35.2M 3.76%
2,712,986
+1,700,000
+168% +$21.1M
ONCT
13
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$28.2M 3.01%
11,357
+7,319
+181% +$16.3M
GTHX
14
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$24.5M 2.61%
660,000
+30,821
+5% +$822K
DBVT
15
DBV Technologies
DBVT
$799M
$23.5M 2.51%
+102,000
New +$24.1M
BPMC
16
DELISTED
Blueprint Medicines
BPMC
$22.9M 2.45%
250,000
– –
RIGL icon
17
Rigel Pharmaceuticals
RIGL
$681M
$18.2M 1.94%
514,000
+200,000
+64% +$8.01M
KURA icon
18
Kura Oncology
KURA
$800M
$15.8M 1.69%
844,789
– –
VKTX icon
19
Viking Therapeutics
VKTX
$3.7B
$13.9M 1.49%
+3,186,000
New +$17.6M
IONS icon
20
Ionis Pharmaceuticals
IONS
$8.6B
$13.8M 1.47%
312,000
-138,000
-31% -$7.01M
NGNE icon
21
Neurogene
NGNE
$656M
$10.5M 1.12%
37,375
+21,750
+139% +$6.01M
LJPC
22
DELISTED
La Jolla Pharmaceutical Company
LJPC
$7.97M 0.85%
267,500
– –
RETA
23
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$6.67M 0.71%
+325,000
New +$8.37M
VIRX
24
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5.78M 0.62%
60,714
+22,857
+60% +$3.92M
SLDB icon
25
Solid Biosciences
SLDB
$794M
$5.63M 0.6%
+50,000
New +$16.9M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Boxer Capital held 35 positions worth $937M, up 71% from $547M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Boxer Capital deployed $279M of net new capital in Q1 2018, opening 9 new positions and adding to 14 existing holdings. Its largest new stake was Loxo Oncology, Inc: 400,000 shares worth $46.1M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $7.01M trimmed.

  • Boxer Capital's largest Q1 2018 buy was Loxo Oncology, Inc: 400,000 shares worth $46.1M.
  • Boxer Capital added most to Wave Life Sciences in Q1 2018, an estimated $33.6M increase.
  • Boxer Capital's biggest Q1 2018 reduction was Ionis Pharmaceuticals, cutting an estimated $7.01M.
  • Boxer Capital fully exited Concert Pharmaceuticals, Inc. in Q1 2018, selling an estimated $10.3M.
  • Boxer Capital's ten largest holdings make up 69% of its $937M portfolio in Q1 2018.
  • Boxer Capital opened 9 new positions and closed 2 in Q1 2018.
  • Boxer Capital's portfolio value rose 71% quarter-over-quarter to $937M.

Based on Boxer Capital's 13F filing for Q1 2018, filed 15 May 2018.